MCM
VIVO

Mazama Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Mazama Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,138
Closed -$44K – 300
2014
Q2 		$44K Buy
+2,138
New +$43.9K 0.01% 223

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Mazama Capital Management's VIVO Position: Q3 2014 in Review

Mazama Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q3 2014, closing a stake of 2,138 shares — an estimated $44K sold.

Mazama Capital Management first reported a position in VIVO in Q2 2014 and held it in 1 quarter. The position peaked at $44K in Q2 2014. 161 funds tracked by Wall St. Rank hold VIVO as of Q3 2014.

  • Mazama Capital Management reported no remaining Meridian Bioscience Inc position as of Q3 2014 after selling out during the quarter.
  • Mazama Capital Management sold 2,138 Meridian Bioscience Inc shares in Q3 2014, an estimated $44K.
  • Mazama Capital Management first reported a position in Meridian Bioscience Inc in Q2 2014 and held it in 1 quarter.
  • Mazama Capital Management's Meridian Bioscience Inc position peaked at $44K in Q2 2014.
  • 161 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2014.

Based on Mazama Capital Management's 13F filing for Q3 2014, filed 12 Nov 2014.